CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL). This study is designe...
Phase 2
Baltimore, Maryland, United States and 32 other locations
or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic...
Phase 3
Bethesda, Maryland, United States and 127 other locations
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; par...
Phase 3
Bethesda, Maryland, United States and 146 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
Northwest WA, Wisconsin, United States and 129 other locations
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic ...
Phase 2
Bethesda, Maryland, United States and 131 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Washington D.C., District of Columbia, United States and 203 other locations
Epcoritamab will be tested either inRelapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as:* Monotherapy, or* Com...
Phase 1, Phase 2
Bethesda, Maryland, United States of America and 80 other locations
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...
Phase 1, Phase 2
Washington D.C., District of Columbia, United States and 83 other locations
of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic...
Phase 3
Bethesda, Maryland, United States and 58 other locations
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic...
Phase 3
York, Pennsylvania, United States and 200 other locations
Clinical trials
Research sites
Resources
Legal